Clinical Trials
Advancing Treatment
Halneuron
CINP-203 is a randomized, phase 2 clinical trial that is evaluating the safety and effectiveness of Halneuron (HAL) vs placebo in people with established neuropathy due to their chemotherapy. Participants will complete laboratory exams (blood work) and questionnaires to evaluate eligibility, safety, and quality of life. If eligible, participants will receive 8 doses of HAL or placebo over 14 days and will be followed for 28 days for safety and effectiveness. CINP-203 will enroll up to 200 people who have Chemotherapy Induced Neuropathic Pain (CINP) due to a Platinum or Taxane based chemotherapy regimen. Participants may be assigned to either an active treatment arm or the placebo control arm of the trial. CINP-203 is currently being enrolled at multiple sites based in the United States.
SP16
SP16 will be the focus of a forthcoming Phase 1b CIPN trial that is fully funded by the National Cancer Institute. The Phase 1b clinical trial will assess SP16 safety and includes exploratory CIPN efficacy assessments and under the leadership of Dr. Patrick Dillon and his research team at the University of Virginia. Patient enrollment is project in the first half of 2026, subject to FDA feedback.
